Tse, Eric http://orcid.org/0000-0002-8351-4722
Kwong, Yok Lam http://orcid.org/0000-0001-8156-6978
Goh, Yeow Tee http://orcid.org/0000-0002-7069-0997
Bee, Ping Chong http://orcid.org/0000-0003-4253-760X
Ng, Soo Chin
Tan, Daryl
Caguioa, Priscilla
Nghia, Huynh
Dumagay, Teresita
Norasetthada, Lalita http://orcid.org/0000-0002-2223-5711
Chuncharunee, Suporn
Radhakrishnan, Vivek http://orcid.org/0000-0001-9484-5669
Bagal, Bhausaheb http://orcid.org/0000-0001-9754-0182
Atmakusuma, Tubagus Djumhana
Mulansari, Nadia Ayu
Article History
Received: 4 November 2022
Accepted: 18 January 2023
First Online: 16 February 2023
Declarations
:
: Eric Tse has received research support from MSD. Priscilla Caguioa has served on scientific advisory boards for Astra Zeneca, Novartis, MSD, Takeda, Otsuka, Johnson and Johnson, and has received research support from Astra Zeneca, Roche, MSD, Mylan, Celltrion, Apellis International, and MorphoSys AG. Teresita Dumagay was the Primary Investigator in the Acalabrutinib Trial sponsored by AstraZeneca and has received an honorarium for separate lectures from Astra Zeneca, Janssen Pharmaceuticals, and Novartis. Vivek Radhakrishna has received advisory fees (institutional) from Pfizer India and institutional grants and/or non-financial support from Intas Pharmaceuticals, Natco Pharmaceuticals, Roche India, BMS, Cipla Pharmaceuticals, Emcure, AstraZeneca, and Dr. Reddy’s Laboratories, outside the submitted work.